
Bispecific antibody combo for NSCLC could extend life by a year
The European Commission (EC) has approved a Marketing Authorisation (MA) for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab). It is approved for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R (L858R)… Read More














